Biohaven (BHVN) Competitors

Roivant Sciences (NASDAQ:ROIV) and Biohaven (NYSE:BHVN) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, media sentiment, dividends, analyst recommendations, profitability, earnings and community ranking.

Which has stronger valuation and earnings, ROIV or BHVN?

Roivant Sciences has higher revenue and earnings than Biohaven. Roivant Sciences is trading at a lower price-to-earnings ratio than Biohaven, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Roivant Sciences	$122.59M	58.27	$4.35B	-$0.15	-66.73
Biohaven	N/A	N/A	-$408.17M	-$9.39	-1.95

Does the media prefer ROIV or BHVN?

In the previous week, Biohaven had 1 more articles in the media than Roivant Sciences. MarketBeat recorded 10 mentions for Biohaven and 9 mentions for Roivant Sciences. Roivant Sciences' average media sentiment score of 1.26 beat Biohaven's score of 0.76 indicating that Roivant Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Roivant Sciences	6 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Biohaven	4 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has more risk & volatility, ROIV or BHVN?

Roivant Sciences has a beta of 1.25, suggesting that its stock price is 25% more volatile than the S&P 500. Comparatively, Biohaven has a beta of 1.33, suggesting that its stock price is 33% more volatile than the S&P 500.

Does the MarketBeat Community prefer ROIV or BHVN?

Biohaven received 352 more outperform votes than Roivant Sciences when rated by MarketBeat users. However, 78.26% of users gave Roivant Sciences an outperform vote while only 67.33% of users gave Biohaven an outperform vote.

Company	Underperform	Outperform
Roivant Sciences	Outperform Votes 54 78.26%	Underperform Votes 15 21.74%
Biohaven	Outperform Votes 406 67.33%	Underperform Votes 197 32.67%

Do analysts rate ROIV or BHVN?

Roivant Sciences presently has a consensus target price of $17.50, indicating a potential upside of 74.83%. Biohaven has a consensus target price of $62.77, indicating a potential upside of 242.81%. Given Biohaven's stronger consensus rating and higher probable upside, analysts plainly believe Biohaven is more favorable than Roivant Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Roivant Sciences	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	3.00
Biohaven	0 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	3.07

Do insiders & institutionals believe in ROIV or BHVN?

64.8% of Roivant Sciences shares are held by institutional investors. Comparatively, 88.8% of Biohaven shares are held by institutional investors. 7.9% of Roivant Sciences shares are held by company insiders. Comparatively, 16.0% of Biohaven shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Is ROIV or BHVN more profitable?

Biohaven has a net margin of 0.00% compared to Roivant Sciences' net margin of -119.54%. Roivant Sciences' return on equity of -14.05% beat Biohaven's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Roivant Sciences	-119.54%	-14.05%	-12.81%
Biohaven	N/A	-225.12%	-158.89%

Summary

Biohaven beats Roivant Sciences on 10 of the 17 factors compared between the two stocks.